- NYTimes, Global Health, Dec. 19, 2021 -
- snip - A growing body of preliminary research suggests the Covid vaccines used in most of the world offer almost no defense against becoming infected by the highly contagious Omicron variant.

All vaccines still seem to provide a significant degree of protection against serious illness from Omicron, which is the most crucial goal. But only the Pfizer and Moderna shots, when reinforced by a booster, appear to have initial success at stopping infections, and these vaccines are unavailable in most of the world.

The other shots — including those from AstraZeneca, Johnson & Johnson and vaccines manufactured in China and Russia — do little to nothing to stop the spread of Omicron, early research shows. And because most countries have built their inoculation programs around these vaccines, the gap could have a profound impact on the course of the pandemic.

The disparity in the ability of countries to weather the pandemic will almost certainly deepen. And the news about limited vaccine efficacy against Omicron infection could depress demand for vaccination throughout the developing world, where many people are already hesitant or preoccupied with other health problems.

Antibodies are the first line of defense induced by vaccines. But the shots also stimulate the growth of T cells, and preliminary studies suggest that these T cells still recognize the Omicron variant, which is important in preventing severe disease.
“What you lose first is protection against asymptomatic mild infection, what you retain much better is protection against severe disease and death,” said John Moore, a virologist at Weill Cornell Medicine in New York. He called it “a silver lining” that Omicron so far appears less lethal than the Delta variant.

The volume and tenor of pleas for help escalated to new heights this past week as India was engulfed in the pandemic.

You’ve likely seen images of numerous funeral pyres and many graves along with sick outside overfull hospitals.

Apart from the pyres, it looks like Wuhan in January 2020, the U.S. in March 2020, and Brazil at the end of this March.

And yet there is something really wrong here, very off. The case counts and deaths are truths which can’t be escaped but the insistence the U.S. somehow is failing to meet India’s needs is off base. - snip -


- snip - In the mean time invective against the Biden administration and Big Pharma has continued, some of it based in what looks like weak and less-than-thorough reporting.

Claims that Big Pharma has decided profits come before the lives of India’s people follow reports that Big Pharma refused to give India patents or transfer intellectual property.

Except that Big Pharma is represented in India by AstraZeneca, which is making their adenovirus-vector vaccine in country. It’s the same vaccine which has been used in Europe, and is still in FDA safety review here.

India also has its own Big Pharma in Bharat Biotech, which has developed Covaxin vaccine in collaboration with Washington University School of Medicine in St. Louis, Missouri. The vaccine left Phase 3 trials in early January.

Yet intelligent people continue to harangue the U.S. and Big Pharma about their refusal to help India with the IP needed for licensing. They retweet stuff like this:



The account that wrote this was opened only weeks ago in January 2021. There’s almost nothing in its profile to suggest this is a human with credible background education or experience; the account hasn’t been validated by Twitter. Note the number of times this has been shared by retweet or quote tweet, yet the majority of roughly 6000 tweets by this account are about pop culture.

This is the kind of social media content which ramped up tension around U.S. response to India’s ongoing COVID surge and continues to do so because it remains uncontested.

The issue the tweet focused on was vaccine manufacturers’ request for indemnification by countries which use its vaccine or licensing to manufacture vaccines. How odd that an account tweeting about beauty products and the Kardashians chose to phrase indemnification this way. - snip -

Except the photo Mr. Rubio posted was not of Mr. Lewis, but of another congressman: Representative Elijah E. Cummings, who died in October. Mr. Rubio also used the photo of himself with Mr. Cummings as his Twitter profile picture for a brief time.

- snip -- The revelation that a coronavirus death took place in the United States in early February shifts the understanding of its arrival in this country and changes the picture of what the nation was contending with by the time government officials began taking action.
-- The first Covid-19 death in the United States had previously been thought to be on Feb. 26 in Seattle, one of the worst-hit cities in the country.
-- Officials in Santa Clara County said Wednesday that a newly discovered coronavirus-linked death Feb. 6, the earliest known death in the United States caused by the virus, was one of more than a dozen deaths in the county that the medical examiner had suspicions about and ordered investigated.

- snip -- The Feb. 6 death was a 57-year-old woman who died at her home in Silicon Valley, officials said Wednesday.
-- The announcement has reset the timeline of the spread of infection in the United States.
-- Officials have said that the death was believed to have been the result of community spread, not travel to another country.

-snip -- In recent weeks, the United States has seen the first rollout of blood tests for coronavirus antibodies, widely heralded as crucial tools to assess the reach of the pandemic in the United States, restart the economy and reintegrate society. But for all their promise, the tests — intended to signal whether people may have built immunity to the virus — are already raising alarms.
- snip -- In Laredo, officials discovered the tests they received were woefully inadequate. The local health department found them to have a reliability of about 20 percent, far from the 93 to 97 percent the company had claimed. A police investigation led to a federal seizure of the tests.
- snip -- More than 90 companies have jumped into the market since the F.D.A. eased its rules and allowed antibody tests to be sold without formal federal review or approval. -snip - Their products vary. Some test only for a transient antibody that spikes while the body is in the throes of an active infection. An antibody that peaks about four weeks after infection and typically marks longer-term immunity is a separate target. There are tests that look for both antibodies; others also look for a third involved in respiratory infections.
- snip -- Rapid tests are by far the easiest to administer. But they are also the most unreliable — so much so that the World Health Organization recommends against their use. Most are manufactured in China. Reports of countries that quickly bought millions have just as swiftly been followed by accounts of poor performance. For example, Britain recently said the millions of rapid tests it had ordered from China were not sensitive enough to detect antibodies except in people who were severely ill. In Spain, the testing push turned into a fiasco last month after the initial batch of kits it received had an accuracy of 30 percent, rather than the advertised 80 percent.
- snip -- In an effort to speed up access, the F.D.A. apparently did not fully consider how these tests would be administered. The agency released a guidance document saying that antibody tests could be performed at “point-of-care” settings, indicating that doctors, nurses and others could give them to patients in their offices. But agency officials also acknowledged that under federal law, if a test has not been authorized by the agency, it must be conducted in so-called high-complexity laboratories, like some large commercial facilities or public health labs. The officials decline to provide additional clarification.

- snip -- Less than 5 percent of the U.S. population may be infected, and even in hot zones like New York or New Orleans, the prevalence may not be higher than 10 to 15 percent, according to Dr. Osterholm. In China, early screening in hard-hit Wuhan indicates that only about 3 percent of the population has antibodies against the new coronavirus.
-- When the proportion of people exposed is that low, the tests’ false positive rate — signaling antibodies where there are none — can limit the tests’ utility.
-- Even Cellex’s F.D.A.-authorized test has a false positive rate of about 5 percent. That is still a significant margin of error: In a community where 5 percent of people have had the virus, Dr. Osterholm said, there would be as many false positives as true ones.

-snip - The episode shows how the military, the most structured and hierarchical part of the government, has tried to adjust to an erratic president, and how in a hollowed-out leadership, acting secretaries have replaced those confirmed by the Senate.
-snip - ... infuriated Mr. Modly. His next actions stunned Pentagon officials and effectively turned the crew of the Roosevelt even more solidly against him. Mr. Modly boarded a Gulfstream business jet at an airfield in suburban Washington and made the 35-hour round-trip flight to Guam, at a cost of $243,116.65, according to a Navy official, confirming a report in USA Today.
- snip - Then he went to the Roosevelt and delivered a 15-minute diatribe over the ship’s loudspeakers berating the crew for cheering for its captain. He called Captain Crozier either “too naïve” or “too stupid” to command an aircraft carrier. He told the sailors they should never trust the media. He blamed China for the virus. Less than 30 minutes later, after taking no questions from the sailors, he was gone.

NYTimes, Opinion, 2-27-2020, Linda Greenhouse

- snip - A few years ago, two Michigan prison inmates, proclaiming themselves adherents of the “Christian Identity” religion, sought the prison’s official recognition to be allowed to conduct their own worship services, apart from other inmates.

- snip - The two prisoners sued under a federal law, the Religious Land Use and Institutionalized Persons Act. They lost in Federal District Court. This month, the United States Court of Appeals for the Sixth Circuit overturned that ruling. The court said the district judge, Phillip Green, had misapplied the law by weighing the prison’s interest in safety as part of his analysis of whether the prison was placing an improper burden on the men’s exercise of their chosen religion.

Say what?
If you just did a double-take, so did I when I came upon this opinion. If you wondered whether the members of the three-judge appellate panel were recent Trump appointees who perhaps share his administration’s desire to elevate religious claims above all else, so did I. They were not.

- snip - The startling fact of the matter is that Judges Griffin, Stranch and Donald were applying the law as they found it — as the Supreme Court has handed it to them in a series of decisions instructing judges to accept almost any religious claim, no matter how preposterous, at face value and to put the government to an extremely tough test to justify any infringement on a “sincere” religious belief.

- snip - Rather than looking at the Sixth Circuit prison decision, Fox v. Washington, as an outlier, we need to see it as a harbinger, a frightening one. I don’t know whether this particular case will end up at the Supreme Court. But there are plenty of cases like it, making claims that would have been dismissed out of hand not too many years ago and that now have to be taken seriously by those of us worried about the growing threat that an increasingly weaponized free-exercise clause poses to civil society, along with the statutes meant to extend its reach.